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ABSTRACT
Objectives: The purpose of the study is to develop a simple, precise, economical, accurate, reproducible, and sensitive method for the estimation of 
famotidine (FAM) in bulk and its pharmaceutical dosage forms by ultraviolet (UV) absorption spectrophotometry.
Methods: The method uses 0.1 N HCl, pH 1.20 as a solvent for the quantitative estimation of FAM in bulk and its tablets dosage form by UV absorption 
spectrophotometry.
Results: FAM exhibited absorbance maxima at 266 nm in 0.1 N HCl, pH 1.20 solvent. The developed method was validated as per the ICH analytical 
method validation guidelines. Beer’s law was obeyed in range of 0-30 µg/ml with r2=0.9998. The limit of detection and limit of quantification values 
of FAM were found to be 0.152 and 0.461 µg/ml, respectively. The mean percentage recovery for developed method was found to be in the range of 
99.35-99.48%, respectively, for the marketed dosage forms. The developed method was also found to be robust and ensures bench-top stability.
Conclusion: The developed method was found to be suitable for the routine quantitative analysis of FAM in bulk and pharmaceutical dosage form. It 
was also concluded that developed UV spectrophotometry method was accurate, precise, linear, reproducible, robust, and sensitive.
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INTRODUCTION
Famotidine (FAM) (Fig. 1) known as 3-([2-(diamino-methyleneamino) 
thiazol-4-yl] methylthio)-N’-sulfamoylpropanimidamide. FAM is 
a potent histamine H2-receptor antagonist used in the treatment 
of duodenal ulcer, peptic ulcer, Zollinger–Ellison syndrome, and 
gastroesophageal reflux disease [1]. FAM has short biological half-
life (~2.5-4 hrs) with site-specific absorption in the upper part of 
the gastrointestinal tract (GIT) with oral bioavailability of 43-50% 
due to the narrow absorption window in GIT and is also stable in 
gastric pH. Therefore, development and validation of a method for 
the estimation of FAM in 0.1 N HCl, pH 1.20 (SGF) would be an ideal 
approach for FAM. The empirical formula and molecular weight of 
FAM are C8H15N7O2S3 and 337.445 g, respectively. Histamine is a 
chemical present mostly in the storage granules of mast cells of the 
body that causes production of acid in the stomach. H2-blockers 
inhibit histamine action and therefore reduce gastric secretion of 
acid produced [2].
The literature survey revealed that various methods of analysis for 
FAM have been reported which includes titrimetry, high-performance 
liquid chromatography, high-performance thin-layer chromatography, 
spectrophotometric, spectrofluorimetric flow injection analysis, 
potentiometry, polarography, etc. [3-10].
Some of these methods have enough sensitivity to determine 
lower concentrations of drug; however, many of these techniques 
are deficient in simplicity, cost-effectiveness, and accessibility. 
Out of these, ultraviolet (UV) spectrophotometry or spectroscopy 
method is characterized by its speed, simplicity, accuracy, and 
inexpensiveness. An UV-spectroscopic method has been reported 
for FAM in 0.1 N HCl, pH 1.20 (SFG) solvent and validated according 
to ICH norms [11].
METHODS
Instrumentation
A double-beam UV-visible spectrophotometer 1800, Shimadzu, 
software version 2.23 using 1 cm matched quartz cell with a slit 
width of 1 mm was used for all the spectral and absorbance 
measurements. The scanning speed was kept medium. Electronic 
weighing balance (Shimadzu analytical balance) was used for 
weighing purpose.
Reagents and chemicals
Pure drug sample of FAM was supplied as a gift sample by Sun 
Pharmaceutical Industry, Dadar, India. Sample was used without 
further purification. Tablets used for analysis were procured from 
local pharmacy. All chemicals and reagents were of analytical grade, 
and double-distilled water was used throughout the investigation to 
develop spectral characteristics.
Selection of solvent
0.1 N HCl, pH 1.20 was selected as a solvent to study the spectral 
characteristics of FAM. It was prepared according to the Indian 
Pharmacopoeia 2014.
Preparation of standard stock solution
Accurately weighed 10 mg pure drug sample of FAM was transferred to 
100 ml (100 µg/ml) calibrated volumetric flask, dissolved, and made 
up to the mark with 0.1 N HCl, pH 1.20. It was the stock solution of FAM 
(100 µg/ml) in 0.1 N HCl, pH 1.20.
Using the stock solution of 100 µg/ml, subsequently dilution was 
carried out by withdrawing different aliquots (0.5, 1.0, 1.5, 2.0, 2.5, 
3.0 ml) from standard solution were transferred into a series of 10 ml 
calibrated volumetric flasks and all were made up to the mark with 
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0.1 N HCl, pH 1.20 to prepare working standard solutions of different 
concentrations (5-30 µg/ml).
Selection of detection wavelength
Solution of FAM in concentration of 10 µg/ml was scanned in the range 
of wavelength 200-400 nm [12]. It was observed that the FAM showed 
considerable absorbance at wavelength of 266 nm. The absorption 
spectrum was found to be sharp and maximum at wavelength of 
266 nm, therefore, it was selected as the wavelength for detection 
in 0.1 N HCl, pH 1.20 (Fig. 2).
Preparation of calibration curve
Solution of FAM in 0.1 N HCl, pH 1.20 in different concentrations (5, 10, 
15, 20, 25, and 30 µg/ml) was taken, and absorbance of these solutions 
was measured against solvent 0.1 N HCl, pH 1.20 as blank at wavelength 
of 266 nm. A calibration curve was plotted from the absorbance values 
so obtained [13,14]. From the calibration curve, it was found that FAM 
obeys Beer’s law in concentrations of 5-30 µg/ml.
Preparation of sample solution
Ten tablets of FAM (Famocid 20) were weighed accurately and 
powdered finely. An accurately weighed quantity of tablets powder 
equivalent to 100 mg of FAM was transferred to a 100 ml volumetric 
flask and diluted with 0.1 N HCl, pH 1.20, and the content was 
ultrasonicated for 20 minutes. The volume was made up to the 
mark with solvent and mixed well. The solutions were further 
filtered using Whatman No. 1 filter paper to remove any unwanted 
particulate matters. The filtered solutions were further appropriately 
diluted with respective solvent to finally produce sample solution of 
concentration 10 µg/ml for analysis. The amount of FAM present in 
the sample solution was determined using the calibration curve of 
standard drug.
Method validation of developed method
The method was validated according to the ICH Q2 (R1) guidelines for 
parameters such as linearity, range, precision, limit of detection (LOD), 
limit of quantification (LOQ), accuracy, recovery, and stability of the 
analyte.
Linearity and range
The linearity of the analytical method was its ability to elicit test results 
which are directly proportional to analyte concentration in samples 
within a given range. Range was determined to know the interval 
between the upper and lower concentrations of analyte (pure FAM) that 
had been demonstrated to determine that the analytical method with a 
suitable level of precision, accuracy, and linearity [15].
To establish the linearity and range of the proposed method, various 
aliquot portions of 0.5-3 ml of FAM stock solution (100 µg/ml) was 
separately transferred into 10.0 ml volumetric flask and diluted up 
to the mark with mobile phase (0.1 N HCl, pH 1.20) to obtain final 
concentrations of 5-30 µg/ml, respectively. The absorbance at each 
concentration was measured against solvent 0.1 N HCl, pH 1.20 as 
blank at a wavelength of 266 nm. Calibration curve was constructed 
by plotting absorbance of FAM (nm) on Y-axis and concentration of 
FAM (µg/ml) on X-axis and regression equation was calculated for the 
drug.
Precision
Precision studies were carried out to ascertain the reproducibility 
of results for the proposed method and used to find out intra- and 
inter-day variations in the test method of FAM. It was determined 
by repeatability [16]. Repeatability was determined by preparing 
three replicates of same concentration of the sample and the 
absorbance was measured. Intraday precision study was carried 
out by preparing drug solution of same concentrations (5, 10, and 
20 µg/ml) and analyzing it at three different times in a day. The 
same procedure was followed for three other days to determine 
interday precision. The results were reported as % relative standard 
deviation (RSD).
LOD and LOQ
LOD is the lowest amount of analyte in the study or test sample that can 
be detected. LOQ is the lowest amount of analyte in the study or test 
sample that can be quantitatively determined by suitable precision and 
accuracy. LOD and LOQ were determined using the following equations 
designated by the ICH guidelines [17].
LOD - 3.3 s/m (1)
LOQ – 10 s/m (2)
Where, s is the standard deviation of the response and m is the slope of 
the related calibration curve.
Accuracy study
Accuracy study was carried out to assure the closeness of the test 
results obtained by the analytical method to the true value [18]. For 
study methods, samples were prepared in triplicate at three different 
concentrations, that is, 10, 15, and 20 µg/ml within the Beer’s law limits 
and absorbance of each concentration was recorded in triplicate (n=3). 
The results were reported as standard deviation and % RSD.
Recovery study
Recovery study was carried out to check accuracy of the proposed 
method by addition of standard drug solution topre-analyzed tablet 
dosage form of FAM sample solution at three different concentration 
levels (75%, 100%, and 125%) within the specified linearity and range. 
The basic concentration level of sample solution selected for spiking 
of the drugs standard solution was 10 µg/ml of FAM for the used 
method. The percentage recovery by proposed method was calculated 
using the formula as below.
Fig. 1: Structure of famotidine
Fig. 2: Ultraviolet spectra of famotidine in 0.1 N HCl (pH 1.20)
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Where accuracy given in:
Percentage relative error= [(Estimated concentration − Total 
concentration)/Total concentration] ×100
E: Total amount of drug estimated (µg/ml),
T: Amount of drug taken from pre-analyzed tablet dosage form (µg/ml),
P: Amount of pure drug added (µg/ml).
Stability study
Stability experiments were performed to evaluate the short-term 
FAM solution stability under different conditions. Experiments were 
performed to determine the stability of bench top (20 hrs). The sample 
was found stable if % deviations are <1%.
Robustness
Robustness was carried out by analyzing FAM concentration on 
different days by different analysts. This study was useful to predict 
the effect of various parameters such as different laboratories, different 
analysts, interday and intraday variations [19-21].
Assay of marketed formulations of FAM
The average weight of 10 tablets of marketed brand of FAM was 
accurately calculated, and these tablets were crushed well into a 
uniform powder. Calculated weight of powdered drug was taken to 
prepare 100 µg/ml stock solution. Three replicates of the test solution of 
10 µg/ml were prepared from dilution of stock solution and sonicated. 
The amounts of FAM were calculated by extrapolating the absorbance 
from the calibration plot. Results of analysis are reported in Table 7.
RESULTS AND DISCUSSION
Linearity and range
The absorbance of FAM at each concentration of 5-30 µg/ml was 
measured against solvent 0.1 N HCl, pH 1.20 as blank at wavelength 
of 266 nm. Calibration curve was constructed by plotting absorbance 
versus concentrations, and regression equation was calculated 
for drug. The equation of calibration curve for FAM obtained was 
y=0.0007+0.0364x, good linearity was observed over the concentration 
range evaluated (5-30 µg/ml) with regression coefficient (r2)=0.9998 
are shown in Fig. 3. The calibration curve was found to be linear for 
the proposed spectrophotometric method in the aforementioned 
concentrations (5-30 µg/ml). The linear regression data for the 
calibration plot are indicative of a good linear relationship between 
peak area and concentration over wide range (Table 1).
Precision
In the intraday study, concentration of drug was calculated on the 
same day at an interval of 2 hrs. In interday study, the concentration 
of drug contents was calculated on three different days within 
laboratory variation. In both intraday and interday precision, the 
study was expressed as RSD of a set of results. The precision of the 
method (% RSD) of FAM for intraday and interday was found to be 
<1% in each concentration showing good repeatability. The values of 
percentage RSD for both intraday and interday precision are shown 
in Table 2.
LOD and LOQ
The LOD and LOQ of FAM by proposed method were determined using 
standard deviation method with calibration standards. The LOD and 
LOQ of the proposed method were found to be 0.152 and 0.461 µg/ml, 
respectively, indicating that the method developed is sensitive and 
without interference of the excipients.
Accuracy study
Accuracy of the method was determined and results of the study showed 
low value of percentage RSD indicating an accurate method (Table 3) as 
well as non-interference with the excipients of the formulation.
Recovery study
To perform the accuracy of the developed method and to study the 
interference of formulation additives, analytical recovery experiments 
were carried out by standard addition method. All value come under 
100±1% (Table 4) that indicate method is accurate.
Stability study
The sample was subjected for short-term stability studies under room 
temperature. The solution was stable for up to 20 hrs. The sample was 
found bench-top stable with % RSD <1 as shown in Table 5.
Robustness
Robustness study showed non-significant difference in the amount of 
drug recovery (% assay) in different laboratory, analyst, and variations 
condition. Robustness study suggested that developed method was 
Fig. 3: Calibration curve of famotidine
Table 1: Various parameters of developed methods of FAM
Parameter Result
Absorption maxima 266 nm









SD: Standard deviation, LOD: Limit of detection, LOQ: Limit of quantification, 
FAM: Famotidine
Table 2: Determination of intraday and interday precision for three different concentrations of FAM
S.No. Normal concentration (µg/ml) Intraday precision (n=3) Interday precision (n=3)
Concentration measured 
(µg/ml) (Mean±SD)
% RSD Concentration measured 
(µg/ml) (Mean±SD)
% RSD
1 5 4.94±0.047 0.96 4.95±0.30 0.62
2 10 9.98±0.30 0.31 9.97±0.025 0.25
3 20 19.94±0.08 0.40 19.94±0.065 0.33
SD: Standard deviation, FAM: Famotidine, RSD: Relative standard deviation
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independent in different parameters of environmental conditions 
(Table 6).
Assay of marketed formulations of FAM
The assay results (% purity) of Facid 20 and Famocid 20 tablets 
were found to be 99.40%±0.45 and 99.55%±0.68, respectively. The 
estimated content (% purity) was in good agreement with the label 
claims (Table 7).
CONCLUSION
A UV-spectrophotometric method was developed and validated as per 
the ICH guidelines for FAM determination in bulk and pharmaceutical 
dosage form. The developed analytical method was found to be simple, 
sensitive, rapid, economical, linear, reproducible, robust, and accurate 
with high interday and intraday precision. The results of the validated 
parameters were found to be satisfactory, and therefore this method 
can be applied successfully for routine quality control analysis of FAM 
in bulk and pharmaceutical formulation.
It can also be employed for the quality control tool in estimation of 
FAM in pharmaceutical dosage forms. The method was found suitable 
to determine concentration of FAM as API or in dosage form precisely 
and accurately. The sample recovery from the formulation using this 
method was very good with respect to its label claim.
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